Protara Therapeutics, Inc. (TARA) Stock Price & Analysis
Protara Therapeutics, Inc. (TARA) fell 1.73% to USD 3.97 as of June 10, 2026 at 00:26 UTC, according to Nexqual real-time market data.
TARA last closed at USD 4.04; the session ranged USD 3.95–4.19 on volume of 982,578 shares. Market capitalization is $223.13M, with a 52-week range of USD 2.77–7.82 (NGM). Source: Nexqual, June 10, 2026 at 00:26 UTC.
Key Statistics (as of June 10, 2026 at 00:26 UTC)
| Price | USD 3.97 |
|---|---|
| Change | ▼ 1.73% (down) |
| Previous Close | USD 4.04 |
| Open | USD 4.1 |
| Day Range | USD 3.95 – 4.19 |
| 52-Week Range | USD 2.77 – 7.82 |
| Volume | 982,578 shares |
| Market Cap | $223.13M |
| Exchange | NGM |
Technical Analysis (TARA)
Nexqual's technical model rates TARA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.32 (neutral) |
| vs SMA50 | Below (USD 4.99) |
| MACD | -0.28 (negative) |
Analyst Ratings (TARA)
Wall Street analysts rate TARA "None" based on 7 analysts, with a mean price target of USD 26.57 (range USD 24–30), per Nexqual as of June 10, 2026 at 00:26 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 26.57 |
| High Target | USD 30 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (TARA)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.31 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.31 vs est -0.37 ▲ beat |
| 2025-12-31 | USD -0.38 vs est -0.31 ▼ miss |
| 2025-09-30 | USD -0.31 vs est -0.39 ▲ beat |
| 2025-06-30 | USD -0.35 vs est -0.41 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:26 UTC.
Financials & Fundamentals (TARA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -37.27% |
| Debt / Equity | 1.69 |
| Current Ratio | 15.69 |
| Total Cash | $135.79M |
| Total Debt | $3.06M |
| Free Cash Flow | $-39.34M |
Source: Nexqual, June 10, 2026 at 00:26 UTC.
Financial Health Score (TARA)
Nexqual rates Protara Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:26 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $136M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$63M |
| Efficiency | Critical — ROE -37%, ROA -24.3% |
Ownership (TARA)
| Insider Ownership | +2.42% |
|---|---|
| Institutional Ownership | +82.36% |
| Shares Outstanding | 56.20M |
| Float | 49.41M |
| Short % of Float | +6.77% |
Source: Nexqual, June 10, 2026 at 00:26 UTC.
Leadership (TARA)
Protara Therapeutics, Inc. is led by Jesse Shefferman (age 53), Co-founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 00:26 UTC.
| Co-founder, CEO, President & Director | Jesse Shefferman (age 53) |
|---|---|
| Chief Financial Officer | Patrick Fabbio (age 57) |
| Senior Vice President of Investor Relations & Corporate Affairs | Justine O'Malley |
| Medical Director of START Carolinas/ Carolina Urologic Research Center | Neal D. Shore F.A.C.S. |
Major Backers & Investors (TARA)
Notable institutional backers of Protara Therapeutics, Inc. include Janus Henderson Group PLC, Velan Capital Investment Management LP, Millennium Management, according to Nexqual as of June 10, 2026 at 00:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 9.26% |
| Velan Capital Investment Management LP | 5.04% |
| Millennium Management | 5.04% |
| Blackstone Inc | 4.03% |
| Sio Capital Management, LLC | 3.5% |
| Acorn Capital Advisors, LLC | 3.12% |
| Integral Health Asset Management, LLC | 3.11% |
| AIGH Capital Management LLC | 2.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.13% |
| Vanguard Group | 7.96% |
Source: Nexqual, June 10, 2026 at 00:26 UTC.
From Protara Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
- The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
- It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LRMR | Larimar Therapeutics, Inc. | USD 3.5 | ▲ 10.41% |
| TRVI | Trevi Therapeutics, Inc. | USD 13.59 | ▲ 1.95% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 3 | ▲ 0.67% |
| MNPR | Monopar Therapeutics Inc. | USD 60.63 | ▲ 1.93% |
| PMVP | PMV Pharmaceuticals, Inc. | USD 1.05 | ▼ 6.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:26 UTC. This page is informational and not investment advice.